

UT M.D. Anderson Cancer Center
Radiology Print by ALONZO, HEATHER R. at 8/15/2008 8:37:59 AM

744652 - BODIN, JEFFREY T 11yo M 05/22/1997 (133.5cm 27.6kg BSA: 1.01m² 06/05/08)

MRI, BRAIN W&W/O CONTRAST 4/22/2008 1:59:00 PM
Accession: 6794686

FULL RESULT:

Examination: MRI of the brain with and without contrast, 04/22/2008.

Clinical History: This is a 10-year-old male with melanoma, rule out metastasis.

Comparison: None.

Findings: There is no abnormal intracranial enhancement or susceptibility signal abnormality to suggest metastasis. There is increased FLAIR hyperintense signal in the sulci of the bilateral cerebral hemispheres likely related to supplemental oxygenation under sedation for MRI scanning in this pediatric patient. There is no acute intracranial finding. There is no significant mass effect, hydrocephalus, or extra-axial collection. The major intracranial flow voids are patent. The globes and orbits are unremarkable. There is circumferential mucosal thickening of the bilateral maxillary sinuses containing air-fluid levels. There is mucosal thickening of the ethmoid air cells and bilateral sphenoid sinuses. The calvarial bone marrow demonstrates no focal abnormalities to suggest osseous metastasis.

IMPRESSION:

1. No evidence for intracranial metastasis.
2. Paranasal sinus disease with fluid levels in the bilateral maxillary sinuses. In the appropriate clinical setting, this may represent acute sinusitis.

11745 - KWON, MICHAEL

SIGNED BY: 11745 - KWON, MICHAEL 4/24/2008 11:41:00 AM

DATE OF INTERPRETATION: {read_dtime}
 TRANS BY: at {trans_dtime}
 ADDENDUM TRANS BY: {add_trans_code}{add_trans_dtime}
 TECHNOLOGIST:

Page: 1 of 2
BODIN/744652

ACCESSION#: 6794686

Children's Hospital

Patient Name	BODIN,JEFFREY	Patient ID	0445573
Birth Date	05/22/1997	Sex	M
Age	11 Year	Exam Status	APPROVED
Exam Procedure	MRI BRAIN W/O & W/CON	Modality	MR
Study Time	08/08/2008 02:20:56	Image Count	246

Diagnostic Report(Radiologists : ARCEMENT, CHRIS)

MR BRAIN WITH AND WITHOUT:

There is a small focus of T2 hyperintensity in the right peritrigonal white matter. There is no associated mass effect or contrast enhancement. The remainder of the brain and ventricular size is within normal limits.

IMPRESSION: SMALL NON-SPECIFIC FOCUS OF T2 HYPERINTENSITY IN THE RIGHT PERITRIGONAL WHITE MATTER, OTHERWISE NORMAL STUDY.

From: "Joseph Hajjar" <jdhajjar@gmail.com>
Subject: **Re: Jeffrey's MRI today**
Date: August 12, 2008 7:38:07 PM CDT
To: "Bodin E-mail" <mjlscamp@bellsouth.net>
Reply-To: jdhajjar@gmail.com

Almost certainly nothing to worry about. The report is quite brief but seems to describe a "small" area of increased water content in a small portion of the white matter of the brain. We see this everyday and do not know why these areas are there. In adults they are even termed UBOs ("unidentified bright objects") and are often seen in "normal" brains. The theories why one tiny area of brain are different in water content ranges from migraine headaches to tiny strokes to development variants to the brain equivalent of birthmark. Regardless of the theory these findings are usually meaningless. If we see 4 or 5 of them we may recommend a follow up exam to make sure they are not a very early manifestation of a disease process like tiny strokes. I bet that you and I have two or three of them in our brains (best not to look). The same finding was likely present on the study at MD Anderson but they did not mention it.

If you want me to look at the exam you can request a cdrom copy of the MRI exam and have them mail it to you or pick it up the next time you are there but it sounds like a nothing to worry about.

How is everything else?

Joe

On Tue, Aug 12, 2008 at 6:17 PM, Bodin E-mail <mjlscamp@bellsouth.net> wrote:
Joe:

Last Friday, Jeffrey had an MRI of the brain done at Children's. The report is attached. Doctor told her nothing to worry about, and no indication of melanoma. But Linda never got a good explanation for what this might be. Doctor said could have been present on MRI done at MD Anderson earlier in year (we don't have that report). We're going to talk to the people in Houston, but do you know what this report is saying? Thanks. Mark

CHILDREN'S HOSPITAL
200 Henry Clay Avenue - New Orleans, LA 70118

REPORT OF ELECTROENCEPHALOGRAPHY

NAME:	BODIN, JEFFREY	AGE:	11 YEARS
HOSPITAL NO:	24306318	MED. REC. NO.:	445573
EXAM DATE:	08/12/08	EEG NO.:	08-637

REFERRING PHYSICIAN: Dr. Morales, Dr. Tilton

MEDICATIONS: Interferon, Keppra.

HISTORY: This is an 11-year old with a history of melanoma. The patient had a reported seizure.

DESCRIPTION: The waking background is characterized by a 10-Hz occipital rhythm that is medium amplitude symmetric and which attenuates with eye opening. Lower voltage faster frequencies are more prominent over anterior head regions. Hyperventilation produces a small amount of background slowing. Hyperventilation is aborted because the patient complains of light-headedness. There is intermittent theta to delta slowing, which is sharply contoured over the left mid to posterior temporal area with some involvement of the left central area and the left frontal area as well (T3-T5 +/- C3-F7). Photic stimulation produces no further abnormalities. There are no clear epileptiform discharges although slowing is often sharply contoured.

IMPRESSION: This is a mildly abnormal electroencephalogram due to the presence of intermittent focal slowing over the left temporal head region.

SHANNON MCGUIRE, M.D.

DD: 08/12/08 DT: 08/13/08

Cc: Dr. Morales
Dr. Tilton

W

Date: 8/18/08

Father's Notes Post my Seizure

ANTI-SEIZURE MESS:

- Keppra
- Topamax
- Lamictal
- Trileptal

INTERFERON alpha-2b Scheduling Cap. (Intram A)

Hi dose → 20 MU/m² 5x/wk 4 wks
 Lo " → 10 MU/m² 3x/wk 48 wks

CHANCE MEL ↓ BY — ? w/ 1 mo hi-dose?

CHANCE MEL ↓ BY — ? w/ 11 mo lo-dose?

SEIZURE DUE HI-DOSE OR THE LO-DOSE?

NO WAY TO TELL (MORALES 8/18/08)

IF I KEEP KEPPRA & RESTART IFN, CHANCE MORE SEIZURES?

OTHER SIDE EFFECTS IFN PERMANENT OR STOP WHEN STOP IFN (e.g. MEMORY PROBLEMS)?

Per Morales (8/18/08), 10 → 20% more people survive 5 yrs if go thru entire IFN treatment.

Per Herzog (4/21/08) - IF ADULT 50% CHANCE RECURRENCE, INT ↓ TO ABOUT 20%. SOME DES THINK BETTER W/ KIDS

ST TAMMANY PARISH HOSPITAL

1202 SOUTH TYLER STREET, COVINGTON, LA 70433

CONFIDENTIALITY/DISCLOSURE WARNING: This transmittal contains PRIVILEGED AND CONFIDENTIAL information intended for use by a physician. Use, copying, or distributing by any other person is strictly prohibited. If you have received this transmittal in error, please notify us by telephone at (885) 898-4427 and return the misdirected transmittal to us by U.S. mail. (See address at top of document) Thank - you.

NAME: BODIN, JEFFREY
SEX: M
LOCATION:
MR#: 28-07-19
PHYSICIAN: SHERRI CASEY
 71107 Hwy 21 Suite 1
 Covington, LA 70433
 (985) 893-2580

PT PHONE: 985-845-0969
DATE OF BIRTH: 05/22/1997
AGE: 11Y
DATE OF EXAM: 02/16/2009
ORD# / FC: 90002 / B
ADM NO: 000377557483
PT CLASS / TYPE: O / P
ADM DATE: 02/16/2009

*****Final Report*****

ACCESSION #: 1791895

Clinical History: 172.9 - SKIN MAL MELANOMA NOS -

MRI BRAIN W/WO CONTRAST - 02/16/2009 metastatic melanoma

RESULT: MRI of the brain

70553

Indication: Headaches, malignant melanoma, rule out metastases

Technique: Sequences performed included axial and sagittal T1 weighted, axial T2 weighted, axial FLAIR, axial proton density, and axial ADC and diffusion weighted images.

Findings:

There is no abnormal enhancement or focal brain parenchymal abnormality evident. Normal enhancement of the pituitary is incidentally noted. Diffusion images demonstrate no acute ischemia. The ventricles and sulci are not enlarged. There is no intracranial hemorrhage, mass or mass effect. The posterior fossa is unremarkable. There is no abnormality of the cerebellum, brainstem or cerebellopontine angles. The sella and optic chiasm are within normal limits. The paranasal sinuses and mastoid air cells are clear.

IMPRESSION:

1. No focal brain parenchymal abnormality or abnormal enhancement.

Interpreting Physician: JOSEPH PERDIGAO M.D.
 Transcribed by / Date: PSC on Feb 16 2009 3:23P
 Approved Electronically by / Date: PERDIGAO M.D., JOSEPH Feb 16 2009 3:23P
Distribution: SHERRI CASEY
 SHERRI CASEY

Name: Jeffrey Bodin | DOB: 5/22/1997 | MRN: 2592229 | PCP: Lauren S Elder, MD

MRI BRAIN W/WO CONTRAST - Details

Study Result

Impression

Normal MRI of the brain with and without gadolinium

Electronically signed by: JOSEPH HAJJAR MD

Date: 10/06/16

Time: 14:58

Narrative

Pre- and post gadolinium (4 cc of Gadovist) images were obtained through the brain. Comparison is made to the previous examination performed 07/14/2014. The brain ventricles appear normal. There is no evidence of mass effect or midline shift. No abnormal extra-axial collections are seen. There is no evidence of restricted diffusion and there is no evidence of abnormal enhancement. Flow voids are seen in the expected locations of the carotid and vertebrobasilar systems.

Images

[Click here to view images](#)

Component Results

There is no component information for this result.

General Information

Ordered by Diane K Africk, MD

Resulted on 10/06/2016 2:58 PM

Result Status: Final result

This test result has been released by an automatic process.

MyChart® licensed from Epic Systems Corporation © 1999 - 2020

EEG

9/4/19

To seen



Jeffrey Bodin

Male, 22 y.o., 5/22/1997

MRN: 1002548110

Phone: 985-520-4713 (W)

PCP: Chno Zzzprovider, MD

Primary Cvg: AETNA BETTER...

NEXT APPT

With Neurology (Monica Noya Santana, MD)
05/27/2020 at 2:30 PM

EEG Awake and Drowsy

Order: 115217182

Status: Final result Visible to patient: No (Not Released) Dx: Grand mal seizure; Narcolepsy due to ...

Details

Narrative

Maxwell Harris Levy, MD 9/4/2019 10:36 AM
Procedure: Routine Outpatient EEG

Clinical information:

Grand mal sz, Narcolepsy due to underlying condition with cataplexy x 10 years -sz on Sunday - since CA treatment. not sleep deprived.

Referring Diagnosis:

Seizures

Medications:

Current Outpatient Medications on File Prior to Encounter

Medication Sig Dispense Refill

• AFLURIA QUAD 2018-2019, PF, 60 mcg/0.5 mL Syrg ADM 0.5ML IM UTD

0

• azelastine (ASTELIN) 137 mcg (0.1 %) nasal spray 1 spray by

Nasal route 2 (two) times daily

• azelastine-fluticasone (DYMISTA) 137-50 mcg/spray Spry 1 spray by Nasal route daily

• buPROPion (WELLBUTRIN XL) 300 MG 24 hr tablet Take 300 mg by mouth daily

• dextroamphetamine-amphetamine (ADDERALL) 20 mg Tab per tablet

Take 30 mg by mouth 3 (three) times daily

• dextroamphetamine-amphetamine (ADDERALL) 30 mg Tab per tablet

TK ONE T PO TID FOR 30 DAYS 0

• fexofenadine (ALLEGRA) 180 MG tablet Take 180 mg by mouth daily

• fluticasone (FLONASE) 50 mcg/actuation nasal



Jeffrey Bodin

Male, 22 y.o., 5/22/1997

MRN: 1002548110

Phone: 985-520-4713 (W)

PCP: Chno Zzzprovider, MD
Primary Cvg: AETNA BETTER...

NEXT APPT

With Neurology (Monica Noya Santana, MD)
05/27/2020 at 2:30 PM

- spray USE ONE
- SPRAY IEN ONCE D 1
- montelukast (SINGULAIR) 10 mg tablet Take 10 mg by mouth daily
- naproxen sodium (ALEVE) 220 MG tablet Take 1,000 mg by mouth 2 (two) times daily with meals
- neomycin-polymyxin-hydrocortisone (CORTISPORIN) 3.5-10,000-1 mg/mL-unit/mL-% otic suspension Place 3 drops into both ears 5 (five) times daily
- olopatadine 0.2 % Drop 1 drop

No current facility-administered medications on file prior to encounter.

Technique:

Digital EEG was recorded in the EEG laboratory on an alert and coherent patient. Recording of EEG, time-locked video, and single-channel EKG was performed with the Natus XLTek EEG machine. Electrodes were placed on the scalp according to the International 10-20 System. The record was reviewed using the Natus Neuroworks EEG software. Default settings: digital filter bandpass of 1-70 Hz, and 60-Hz notch, sensitivity setting of 7 uV/mm, and time base of 30 mm/s. When necessary, the settings were adjusted during the review process. The patient was awake or asleep during the study. Activation consisted of hyperventilation.

EEG Findings:

• Waking background activity: bisymmetric 11-Hz alpha rhythm; posteriorly dominant, medium amplitude, well organized, reactive to eye opening.



Jeffrey Bodin

Male, 22 y.o., 5/22/1997

MRN: 1002548110

Phone: 985-520-4713 (W)

PCP: Chno Zzzprovider, MD
Primary Cvg: AETNA BETTER...

NEXT APPT

With Neurology (Monica Noya Santana, MD)
05/27/2020 at 2:30 PM

- Sleep background activity: bisymmetric central theta activity, vertex waves, sleep spindles, and K complexes.
- No epileptiform activity.
- No abnormalities with hyperventilation.

Interpretation:

Normal awake and sleeping EEG

Interpreting Fellow/Resident: Maxwell Levy MD

Interpreting Faculty/Staff: Piotr Olejniczak MD

Last Resulted: 09/04/19 10:30

- Order Details
- View Encounter
- Lab and Collection Details
- Routing
- Result History

🕒 Routing History

Priority	Sent On	From	To	Message Type
	9/4/2019 1:15 PM	Piotr W. Olejniczak, MD	Piotr W. Olejniczak, MD	Results

9/19/19

Nerve
Study
Conduction

LSUHSC-NO NEUROLOGY
EMG LABORATORY
478 S Johnson St, 5th Floor
New Orleans, LA 70112
504-412-1517

Full Name: Jeffrey Bodin Gender: Male
Patient ID: 2327610 Date of Birth: 5/22/1997

Visit Date: 9/19/2019 11:17
Age: 22 Years 3 Months Old
Examining Physician: Michael P. Charlet, M.D.
Referring Physician: Dr. Joseph Gonzales

Patient History: 22 y/o M with malignant melanoma. Patient states a history of polyneuropathy after treatment for melanoma. Currently patient complaining of pain and numbness in bilateral arms and legs. On neurological examination, strength is normal. Deep tendon reflexes are symmetrical.

Findings: NCS were performed on the right upper and bilateral lower extremities and were normal. EMG of bilateral upper and lower extremities was normal.

Impression: Normal study without significant evidence of polyneuropathy or radiculopathy

Thank you for this consultation.



Michael P. Charlet, M.D.

9/19/19
Nerve Con Study

Sensory NCS

Nerve / Sites	Rec. Site	Onset Lat ms	Peak Lat ms	NP Amp μ V	Segments	Distance cm	Velocity m/s
R Median, Ulnar - Digital Antidromic							
Median Wrist	D2	2.19	3.07	69.3	Median Wrist - D2	13	59
Median Wrist	D3	2.19	3.02	56.0	Median Wrist - D3	13	59
Median Wrist	Palm	1.51	1.98	65.6	Median Wrist - Palm	8	53
Ulnar Wrist	D5	2.29	3.18	42.7	Ulnar Wrist - D5	11.5	50
R Radial - Anatomical snuff box (Forearm)							
Forearm	Wrist	1.88	2.55	42.1	Forearm - Wrist	10	53
R Medial antebrachial cutaneous - Forearm (Elbow)							
Elbow	Forearm	2.19	2.71	13.6	Elbow - Forearm	12	55
R Sural - Ankle (Calf)							
Calf	Ankle	3.49	4.27	18.5	Calf - Ankle	14	40
L Sural - Ankle (Calf)							
Calf	Ankle	3.54	4.32	17.9	Calf - Ankle	14	40

Motor NCS

Nerve / Sites	Muscle	Latency ms	Amplitude mV	Amp % %	Duration ms	Area mVms	Segments	Distance cm	Lat Diff ms	Velocity m/s
R Median - APB										
Wrist	APB	3.02	12.8	100	6.98	54.7	Wrist - APB	7		
Elbow	APB	7.45	12.1	94.8	7.34	55.0	Elbow - Wrist	26.2	4.43	59
R Ulnar - ADM										
Wrist	ADM	2.76	11.1	100	7.55	54.0	Wrist - ADM	7		
B.Elbow	ADM	6.30	11.5	103	8.18	52.1	B.Elbow - Wrist	20	3.54	56
A.Elbow	ADM	8.59	11.4	102	8.02	51.9	A.Elbow - B.Elbow	14	2.29	61
R Peroneal - EDB										
Ankle	EDB	5.52	6.1	100	8.39	29.1	Ankle - EDB	8		
Fib head	EDB	13.49	6.0	99.1	8.85	30.8	Fib head - Ankle	35	7.97	44
Pop fossa	EDB	15.83	6.6	110	8.65	32.4	Pop fossa - Fib head	9.5	2.34	41
L Peroneal - EDB										
Ankle	EDB	4.32	7.2	100	7.24	30.0	Ankle - EDB	8		
Fib head	EDB	11.77	7.5	104	7.19	29.8	Fib head - Ankle	33.5	7.45	45
Pop fossa	EDB	13.23	8.4	116	7.14	32.7	Pop fossa - Fib head	7	1.46	48
R Tibial - AH										
Ankle	AH	4.69	15.9	100	8.02	70.7	Ankle - AH	8		
Pop fossa	AH	13.18	13.8	86.6	8.80	71.0	Pop fossa - Ankle	39	8.49	46
L Tibial - AH										
Ankle	AH	4.43	19.4	100	7.71	61.4	Ankle - AH	8		
Pop fossa	AH	12.71	17.4	89.7	8.44	63.9	Pop fossa - Ankle	38.5	8.28	46

H Reflex

Nerve	H Lat ms
L Tibial - Soleus	30.00
R Tibial - Soleus	29.95

9/19/19
Nerve Con Study

EMG

EMG Summary Table										
Muscle	Spontaneous				MUP Recruitment					
	Fib	PSW	Fasc	Other	#	Rate	Polys	Dur	Amp	Effort
L. Biceps brachii	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Triceps brachii	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Pronator teres	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Extensor digitorum communis	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. First dorsal interosseous	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Abductor pollicis brevis	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Biceps brachii	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Triceps brachii	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Pronator teres	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Extensor digitorum communis	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. First dorsal interosseous	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Abductor pollicis brevis	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Tibialis anterior	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Gastrocnemius	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Vastus medialis	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Extensor hallucis longus	None	None	None		Normal	Normal	None	Normal	Normal	Max
R. Tibialis posterior	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Tibialis anterior	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Gastrocnemius	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Vastus medialis	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Extensor hallucis longus	None	None	None		Normal	Normal	None	Normal	Normal	Max
L. Tibialis posterior	None	None	None		Normal	Normal	None	Normal	Normal	Max

Campus Multispecialty Clinic 5th Floor
478 South Johnson St Floor 5
New Orleans, LA 70112
(504) 412-1517
(504) 412-1538

Patient: JEFFREY BODIN
528 BEAU CHENE DR
MANDEVILLE, LA 70471

Home: (985) 520-4713
Work:

EMRN: 2327610
Age/DOB: 23 05/22/1997
Encounter Date: 04/20/2020

Reason For Visit

Follow-up visit for seizure disorder care. This telemedicine visit was initiated by the provider using a Zoom video-capable platform that was offered to the patient, even if the visit ended up being an audio only call. If it was determined that an in-person physical examination or a higher level of care was indicated or if other diagnostic testing was needed, the patient was referred to the appropriate resources. The patient verbally consented to this telemedicine visit due to restrictions of the COVID-19 pandemic, after all questions were answered.

History of Present Illness

Handedness: right handed
 Seizure Onset: 09/2008
 Last Seizure: 02/28/2020
 Seizure frequency: previous seizure in 12/2020
 Seizure intervention: not on antiseizure medication
 Etiology, Seizure type, or Epilepsy syndrome: NOS, NES?; shaking upon waking up
 Querying and Intervention for side effects of anti-seizure therapy: N/A
 Personalized Epilepsy Safety Issue and Education provided:
 Screening for Psychiatric or Behavioral Health Disorders:
 Counseling for Women of Childbearing Potential with epilepsy:
 Referral to Comprehensive Epilepsy Center: N/a
 Quality of life assessment: Done

Allergies

- 1. Latex Gloves

Current Meds

Medication Name	Instruction
24HR Allergy Relief 180 MG Oral Tablet	TAKE 1 TABLET DAILY
Amphetamine-Dextroamphetamine ER 30 MG Oral Capsule Extended Release 24 Hour	TAKE 3 CAPSULE DAILY
Azelastine HCl - 0.1 % Nasal Solution	USE 1 SPRAY IN EACH NOSTRIL TWICE DAILY
buPROPion HCl ER (XL) 300 MG Oral Tablet Extended Release 24 Hour	TAKE 1 TABLET DAILY.

Epilepsy Note

Patient: JEFFREY BODIN
Encounter: Apr 20 2020 11:30AM

EMRN: 2327610

Fluticasone Propionate 50 MCG/ACT Nasal Suspension	USE 2 SPRAYS IN EACH NOSTRIL ONCE DAILY
Montelukast Sodium 10 MG Oral Tablet	TAKE 1 TABLET AT BEDTIME.
Sunosi 75 MG Oral Tablet	

Review of Systems

Constitutional no weight loss, no fever; continuing treatment for myeloma
Respiratory negative
CV negative
Eyes negative
GI negative
ENT negative
Skin left leg scar(myeloma surgery)
GU negative
Musculoskeletal post dislocation surgery
Hematologic Myeloma on remission
Neurologic left leg diminished tactile sensory
Endocrine negative
Allergic seasonal allergies. Latex allergy

Sleep Issues:negative

Chronic Medical Issues: myeloma, narcolepsy, seizure disorder

Employment/School: N/A

Recent Stressors: Covid pandemic

Results/Data

EMG (Dr. Charlet 9/19/2019): normal study (claimed polyneuropathy post melanoma therapy)
EEG (UMC 9/4/2019): 11 Hz alpha rhythm when awake; normal awake and sleep
EEG Reviewed (Ochsner 9/19/2018) : normal EEG with the patient awake and asleep
MRI of Brain Reviewed (without and with contrast 10/06/2016): normal MRI of the brain with and without gadolinium
MSLT (MD Anderson Houston 8/5/2016): mean sleep onset latency 5.9 minutes. 4 SOREMPs

Physical Exam

Appearance not in acute distress - as per zoom video and patient report
Orientation oriented x 3.
Memory intact
Attn Span/Concentration intact
Language fluent
Fundi wnl
Visual Field wnl
EOM (Nystagmus?) negative
Muscle Strength 5/5 all extremities, but right shoulder 3/5
Muscle Tone wnl
Sensation intact, but left leg diminished.
Reflexes reduced ankle reflexes b/l, no clonus
Coordination intact finger-nose
Gait and Station wnl.

Assessment

Epilepsy Note

Patient: JEFFREY BODIN
Encounter: Apr 20 2020 11:30AM

EMRN: 2327610

1. Intractable epilepsy without status epilepticus, unspecified epilepsy type (G40.919)
2. Narcolepsy (G47.419)

Could not assess in person outside of video zoom assessment and patient report. No significant interval change as compared to the previous visit.

~~Could not assess in person outside of video zoom assessment. No significant interval change~~

Discussed

Spent greater than 15 minutes face to face: greater than 50 % in counseling or Coordination of care

Plan

1. The patient needs inpatient Video-EEG monitoring - would perform as soon as Covid-19 pandemic emergency status would allow elective procedures
2. RTC after monitoring or if emergency

Education

State laws regarding driving have been reviewed with the patient.

Counseling has been provided about risks of seizures including SUDEP as well as risk with anti-epileptic therapy.

Signatures

Electronically signed by : PIOTR OLEJNICZAK, M.D.; Physician Apr 21 2020 8:50AM CST

(Author)

Electronically signed by : PIOTR OLEJNICZAK, M.D.; Physician May 12 2020 8:16AM CST

(Author)

Campus Multispecialty Clinic 5th Floor
478 South Johnson St Floor 5
New Orleans, LA 70112
(504) 412-1517
(504) 412-1538

Patient: JEFFREY BODIN
528 BEAU CHENE DR
MANDEVILLE, LA 70471

Home: (985) 520-4713
Work:

EMRN: 2327610
Age/DOB: 23 05/22/1997
Encounter Date: 09/28/2020

Reason For Visit

Follow-up visit for seizure disorder care and narcolepsy. Former patient of Dr. Caroline Barton co-managed with another neurologist. Patient presents today for follow up. He has history of seizures but he is not on any AED. He states that last time he had a GTC seizure was in 2016. He reports multiples episodes of lack of awareness and like "mild seizure events" where he does not loss consciousness. Patient also has narcolepsy w/o cataplexy, he is taking amphetamine-dextroamphetamine ER (prescribed by another neurologist) which helps with his daytime symptoms. Patient states that he has being able to gain some weight and do more important stuffs since he is on this medication. He visit another neurologist (specialist in sleep medicine) for this last complaint. Patient asked about his pending EMU admission to localized/characterize his seizure like activity.

History of Present Illness

Handedness: right handed
 Seizure Onset:09/2008
 Last Seizure: Poorly defined frequent auras. Last GTC seizure was in February of 2016. Last "small" seizure was in February of 2020
 Seizure frequency: previous seizures in 12/2020; 02/28/2020
 Seizure intervention: not on antiseizure medication
 Etiology, Seizure type, or Epilepsy syndrome: NOS, NES?; shaking upon waking up
 Querying and Intervention for side effects of anti-seizure therapy: N/A
 Personalized Epilepsy Safety Issue and Education provided:
 Screening for Psychiatric or Behavioral Health Disorders:
 Counseling for Women of Childbearing Potential with epilepsy:
 Referral to Comprehensive Epilepsy Center: N/a
 Quality of life assessment: Done

Allergies

- 1. Latex Gloves

Current Meds

Medication Name	Instruction
24HR Allergy Relief 180 MG Oral Tablet	TAKE 1 TABLET DAILY
Amphetamine-Dextroamphet ER 30 MG Oral Capsule Extended Release 24 Hour	TAKE 3 CAPSULE DAILY

Epilepsy Note

Patient: JEFFREY BODIN
Encounter: Sep 28 2020 12:30PM

EMRN: 2327610

Azelastine HCl - 0.1 % Nasal Solution	USE 1 SPRAY IN EACH NOSTRIL TWICE DAILY
buPROPion HCl ER (XL) 300 MG Oral Tablet Extended Release 24 Hour	TAKE 1 TABLET DAILY.
Fluticasone Propionate 50 MCG/ACT Nasal Suspension	USE 2 SPRAYS IN EACH NOSTRIL ONCE DAILY
Montelukast Sodium 10 MG Oral Tablet	TAKE 1 TABLET AT BEDTIME.
Sunosi 75 MG Oral Tablet	

Review of Systems

Constitutional no weight loss, no fever; continuing treatment for myeloma
Respiratory negative
CV negative
Eyes negative
GI negative
ENT negative
Skin left leg scar(myeloma surgery)
GU negative
Musculoskeletal post dislocation surgery
Hematologic Myeloma on remission
Neurologic left leg diminished tactile sensory
Endocrine negative
Allergic seasonal allergies. Latex allergy

Sleep Issues:negative

Chronic Medical Issues: myeloma, narcolepsy, seizure disorder

Employment/School: N/A

Recent Stressors: Covid pandemic

Results/Data

EMG (Dr. Charlet 9/19/2019): normal study (claimed polyneuropathy post melanoma therapy)
EEG (JMC 9/4/2019): 11 Hz alpha rhythm when awake; normal awake and sleep
EEG Reviewed (Ochsner 9/19/2018) : normal EEG with the patient awake and asleep
MRI of Brain Reviewed (without and with contrast 10/06/2016): normal MRI of the brain with and without gadolinium
MSLT (MD Anderson Houston 8/5/2016): mean sleep onset latency 5.9 minutes. 4 SOREMPs

~~Constitutional no weight loss, no fever; continuing treatment for myeloma
Respiratory negative
CV negative
Eyes negative
GI negative
ENT negative
Skin left leg scar(myeloma surgery)
GU negative
Musculoskeletal post dislocation surgery
Hematologic Myeloma on remission
Neurologic left leg diminished tactile sensory
Endocrine negative
Allergic seasonal allergies. Latex allergy~~

~~Sleep Issues:negative~~

Epilepsy Note

Patient: JEFFREY BODIN
Encounter: Sep 28 2020 12:30PM

EMRN: 2327610

~~Chronic Medical Issues: myeloma, narcolepsy, seizure disorder~~

~~Employment/School: N/A~~

~~Recent Stressors: Covid pandemic~~

Vitals

Adult Vital Signs

	Recorded: 28Sep2020 10:21AM
Height	5 ft 7 in
Weight	98 lb 12.8 oz
BMI Calculated	15.47
BSA Calculated	1.5
Systolic	111, Sitting
Diastolic	78, Sitting
Heart Rate	91
Pulse Quality	Normal
Pain Scale	0

Physical Exam

Appearance not in acute distress, mildly anxious.
Orientation oriented x 3.
Memory intact
Attn Span/Concentration intact
Language fluent
Fundi wnl
Visual Field wnl
EOM (Nystagmus?) negative
Muscle Strength 5/5 all extremities, but right shoulder 3/5
Muscle Tone wnl
Sensation intact, but left leg diminished.
Reflexes reduced ankle reflexes b/l, no clonus
Coordination intact finger-nose
Gait and Station wnl.

Assessment

1. Intractable epilepsy without status epilepticus, unspecified epilepsy type (G40.919)
2. Narcolepsy (G47.419)

Discussed

Spent greater than 25 minutes face to face: greater than 50 % in counseling or Coordination of care

Plan

1. Educated about medication side effect
2. Epworth sleepiness scale applied today (score 24 w/o medication and 0 with medication)
3. Would refer for inpatient/observation (off AED meds already) Video-EEG monitoring for frequent persistent auras/focal seizures to establish need for therapy
4. Follow up in 3 months

Epilepsy Note

Patient: JEFFREY BODIN
Encounter: Sep 28 2020 12:30PM

EMRN: 2327610

- ~~1. Educated about medication side effect~~
- ~~2. Epworth sleepiness scale applied today (score 24 w/o medication and 0 with medication)~~
- ~~3. Would refer for inpatient/observation (off AED meds already) Video-EEG monitoring for frequent persistent auras/focal seizures to establish need for therapy~~
- ~~4. Follow up in 3 months~~

Education

State laws regarding driving have been reviewed with the patient.
Counseling has been provided about risks of seizures including SUDEP as well as risk with anti-epileptic therapy.

Attending Note

I have performed a history and physical exam on Mr. JEFFREY BODIN with Dr. Losada and discussed the management of the patient with the resident. I reviewed the resident's note and agree with the documented findings and plan of care and I have indicated above.

Signatures

Electronically signed by : PIOTR OLEJNICZAK, M.D.; Physician Sep 28 2020 12:18PM CST
(Co-author)

Electronically signed by : PIOTR OLEJNICZAK, M.D.; Physician Oct 13 2020 11:03AM CST (Author)

AETNA BETTER HEALTH® OF LOUISIANA
Prior authorization form



Phone: 1-855-242-0802
Fax: 1-844-227-9205

Date of Request: 10/15/2020

For urgent requests (required within 24 hours), call Aetna Better Health of Louisiana at 1-855-242-0802

MEMBER INFORMATION

Name: BODIN,JEFFREY ID Number 5794038645696
Date of Birth: 05/22/1997 Physician Name: DR. PIOTR OLEJNICZAK
Other Insurance: N/A Gender (circle one): F M

REQUESTING PHYSICIAN OR PROVIDER INFORMATION

Referring Provider / Requesting Provider Name: <u>DR. PIOTR OLEJNICZAK</u>	Place of Service or Facility Name Name: <u>University Medical Center New Orleans</u>
Address: <u>2000 Canal St New Orleans LA 70112</u>	Address: <u>2000 Canal St New Orleans LA 70112</u>
Telephone #: <u>504-702-4800 ext 0328</u>	Telephone #: <u>504-702-3000</u>
Fax #: <u>504-962-6484</u>	Fax #: <u>504-962-6484</u>
Specialty: <u>Neurology</u>	Specialty: <u>ACUTE CARE FACILITY</u>
National Provider Identification (NPI): <u>1942221965</u>	National Provider Identification (NPI): <u>1568403111</u>
Contact Person: <u>Tamara Landry</u>	Contact Person: <u>Tamara Landry</u>

REFERRAL / AUTHORIZATION INFORMATION

Problem / Diagnosis (ICD-9 Code(s)): G40.919/ Medically Intractable Epilepsy;
G47.419/ Narcolepsy

Procedure / Test Requested (CPT Code(s)): 95720, 95716 Video-EEG monitoring in
the Inpatient Epilepsy Monitoring Unit

Date of Appointment or Service: 10/26/20-10/29/20 Number of Visits Required: 3 days

Type of Procedure (circle one): Inpatient Outpatient In Office

Other Clinical Information - Include clinical notes, lab and X-ray reports, etc. (For procedures, please attach additional pages as necessary.): Please see attached

Problem List

- Melanoma in situ of left lower leg
- Migraine-cluster headache syndrome
- Peripheral neuropathy
- Inflammatory neuropathy
- Bilateral impacted cerumen

Health Maintenance

- 05/22/1999 Annual Wellness
- 09/01/2020 Influenza Vaccine
- 11/05/2029 Tetanus-Diphtheria-Pertusis (DTap-Tdap-Td) (9 - Td)
- 05/22/2062 Pneumococcal Vaccine: 65+ Years (1 of 2 - PCV13)

Tobacco History

Smoking Status Never Smoker
Smokeless Tobacco Status Never Used

Medical History

- 2016 Clinical trial participant
- 02/15/2015 Narcolepsy
- Date Unknown Cancer
- Date Unknown Dislocated shoulder
- Date Unknown Melanoma in situ of left lower leg
- Date Unknown Migraine-cluster headache syndrome
- Date Unknown Migraines
- Date Unknown Peripheral neuropathy
- Date Unknown Prematurity
- Date Unknown Seasonal allergies
- Date Unknown Seizure syndrome

Surgical History

Surgical History

- 2015 Wisdom tooth extraction
- Date Unknown Adenoidectomy w/ myringotomy and tubes
- Date Unknown Appendectomy
- Date Unknown dislocated shoulder [Other] (Right)
- Date Unknown gum graft [Other]
- Date Unknown melanoma excision [Other]
- Date Unknown Tonsillectomy

Care Team and Communications

PCPs	Type
Callie Anne Linden, MD	General
Other Patient Care Team Members	
Relationship	
Laura Conway Williams, MD	Attending
Ashley Lena Weiss, DO	Consulting Physician
Dana Marie Leblanc, MD	Pediatrician
Curry Antoine, CNA	Not specified
Dominique R Banks, MA	Medical Assistant
Carolyn Haley, RN	Registered Nurse
Elizabeth Aronson, RN	Registered Nurse

Recipients of Past 2 Communications

Office Visit - 8/31/2018		
Children's Hospital Dermatology	8/31/2018	Mail
Chno Zzzprovider, MD	8/31/2018	Mail

Sep 25



Telephone with Derm - Stevens, J

Vitals from encounters over the past 365 days

	9/29/20	8/27/20
BP	112/91	--
Pulse	83	--
Resp	16	--
Temp	97.6 °F (36.4 °C)	97.7 °F (36.5 °C)
Temp src	Temporal	Temporal
SpO2	--	--
Weight	45.2 kg (99 lb 9.6 oz)	45.1 kg (99 lb 6.4 oz)
Height	1.702 m (5' 7")	1.715 m (5' 7.5")
Pain Score	0	--

Allergies

- Lactose Nausea And Vomiting, Diarrhea
- Latex Rash

Medications

Outpatient Medications

- AFLURIA QUAD 2018-2019, PF, 60 mcg/0.5 mL Syrg
- azelastine (ASTELIN) 137 mcg (0.1 %) nasal spray
- dextroamphetamine-amphetamine (ADDERALL) 30 mg Tab per tablet
- fexofenadine (ALLEGRA) 180 MG tablet
- fluticasone (FLONASE) 50 mcg/actuation nasal spray
- montelukast (SINGULAIR) 10 mg tablet

Clinic-Administered Medications

- lidocaine (PF) (XYLOCAINE) 10 mg/mL (1 %) injection 2 mL
- lidocaine (PF) (XYLOCAINE) 10 mg/mL (1 %) injection 2 mL
- triamcinolone acetonide (KENALOG-40) 40 mg/mL injection 40 mg
- triamcinolone acetonide (KENALOG-40) 40 mg/mL injection 80 mg
- triamcinolone acetonide (KENALOG-40) 40 mg/mL injection 80 mg

Preferred Pharmacies

- WALGREENS DRUG STORE #05382 - MANDEVILLE, LA - 4330 985-674-2551
- HIGHWAY 22 AT SEC OF ACCESS ROAD & HWY 22 985-674-5334

Immunizations/Injections

- DTaP 6/8/2001, 11/24/1998, 11/21/1997, ...
- HPV (Gardasil-4) 5/20/2013, 7/19/2011, 5/18/2011
- Hepatitis A, Pediatric/Adolescent 11/27/2007, 4/18/2007
- Hepatitis B, Pediatric/Adolescent 2/26/1998, 6/26/1997, 5/27/1997
- Hib Unspecified 8/25/1998, 11/21/1997, 9/23/1997, ...
- INFLUENZA, SEASONAL, INJECTABLE, (PF) 11/16/2017
- IPV 6/8/2001, 8/25/1998, 9/23/1997, ...
- Influenza, Injectable, MDCK, Preservative Free, Quadrivalent 11/5/2019
- Influenza, Seasonal, Injectable 11/25/2013, 11/25/2013, 9/16/2010, ...
- Influenza, Unspecified 11/16/2017, 9/16/2010, 9/9/2009, ...
- Influenza, injectable, quadrivalent, preservative free 10/5/2016, 11/4/2015
- MMR 6/8/2001, 5/26/1998
- Meningococcal MCV4P 5/26/2015, 5/18/2009
- Pneumococcal Conjugate PCV 12/15/2000
- Pneumococcal Conjugate PCV 13 2/19/2015
- Pneumococcal Polysaccharide PPSV 23 11/5/2019
- TST-PPD intradermal 11/4/2015, 5/20/2013, 5/17/2013
- Tdap 11/5/2019, 7/14/2015, 5/18/2009
- Varicella 5/10/2007, 5/26/1998

Mr. **Jeffrey Bodin** is a 23-year-old man with history of medically intractable epilepsy since 09/2008. The patient continues to experience frequent daily sensory events/seizures which he describes as auras. In addition to the auras, the patient has had longer and more pronounced episodes with alteration of awareness which occur every several months. Last generalized tonic-clonic convulsion occurred in 2016. The routine EEG from 09/04/20219 did not capture evidence of epileptiform activity, similar to previous EEG studies. MRI of the brain from 10/06/2016 was normal as well. Patient's quality of life has suffered from intractable seizures and side effects of medications. Due to perceived lack of anti-epileptic drugs (AEDs) efficacy and their side effect profile which include potential interactions with his other medications, the patient has been refusing to be re-challenged with AEDs. Secondary generalized convulsions pose a direct risk of death from SUDEP (sudden unexpected death in epilepsy). The co-morbidities include multiple myeloma treated at MD Anderson and narcolepsy objectively verified among others by the multiple sleep latency test (MSLT). The allergies include latex gloves.

Diagnosis: G40.919 Medically intractable epilepsy, undetermined if focal or generalized
G47.419 Narcolepsy

The patient suffers from medically intractable epilepsy. In order to record representative seizures to allow their precise localization and classification, she needs inpatient Video-EEG monitoring with scalp electrodes primarily to guide future therapy, be it pharmacological or surgical. If the seizures turn out to be non-epileptic (e.g related to sleep/wake phenomena with narcolepsy), the therapy will need to change as well and the patient may not need anti-epileptic medications. The patient will be admitted to the Epilepsy Monitoring Unit at the University Medical Center in New Orleans on 10/26/2020. Because of the possibility of uncontrolled seizures, the patient will be equipped with an IV access for administration of rescue medications if necessary. If no seizures will be captured on the day of admission, the seizure activation protocol will be implemented. It includes overnight sleep deprivation followed in the morning by photic stimulation, hyperventilation and physical exercise. After recording sufficient number of representative events allowing appropriate diagnosis to guide future therapy, the patient, if medically stable, will be discharged home with recommendation to follow with Dr. Olejniczak at the LSUHN Epilepsy Clinic in New Orleans

Piotr Olejniczak, MD
Diplomat, ABPN with subspecialty in Epilepsy